Blockchain

Polkadot Enhances Decentralization in Ecosystem Growth With the Launch of PolkaPort East in Hong Kong

HK, HK, June 5th, 2024, Chainwire

Web3 Foundation, the entity supporting the growth of the Polkadot ecosystem, has awarded a grant to PolkaPort East. The Decentralized Futures (DF) grant is designed to help further decentralize Polkadot while spearheading technical, community, and broader ecosystem adoption.

PolkaPort East is an independent entity leading investor relations and growth initiatives for Polkadot centered on Hong Kong and the Greater Bay Area. The DF grant from the Web3 Foundation is the first such award to be received by an organization working in Asia.

The grant will support PolkaPort East’s goals of leading investor relations and growth for Polkadot in the region. Its mandate also includes promoting Polkadot and its technology, and acting as a key regional driver of capital into the ecosystem.

Max Rebol, co-founder of PolkaPort East and CEO of Harbour Industrial Capital, a Polkadot-focused VC fund, said: “The launch of PolkaPort East comes at a crucial moment for Polkadot. It represents a critical step towards increasing the network’s decentralization while strengthening the ecosystem’s strategic position in Hong Kong. Thibault Perréard, also a co-founder who heads up strategy for Bifrost, a leading Polkadot parachain added: “With the support of the DF grant, PolkaPort East will be tapping into the thriving innovation hubs of Hong Kong and the Greater Bay Area while engaging and fostering relationships with local governments, global enterprises and capital allocators of the region.” 

Vincent Chan, the third co-founder of PolkaPort East who formerly led growth initiatives at Parity Technologies, explained that following the receipt of the DF grant, the initiative will seek to attract participants to the Polkadot ecosystem across Asia. These include projects and developers looking to build on Polkadot, Polkadot-native VCs, funds, and capital allocators, as well as general web3 investors. It will also target Asian university blockchain collectives and associations, fintechs seeking to enter web3, and local government exploring the use of blockchain technology.

Speaking on behalf of the Web3 Foundation, David Hawig, the Director of Ecosystem, stated “The Web3 Foundation is thrilled to support the Polkaport East initiative through a Decentralized Futures grant. This project exemplifies our commitment to fostering decentralized access and innovation within the Polkadot ecosystem. We believe Polkaport East will play a pivotal role in enhancing connectivity and empowering the community in Hong Kong, driving forward the vision of a truly decentralized internet.”

About Decentralized Futures 

The DF initiative developed by Web3 Foundation is designed to kickstart independent teams and initiative that will drive Polkadot’s success. It was established in 2023 following the restructuring of Parity Technologies which offloaded responsibilities for investor relations, growth and marketing to focus solely on technical development.

Through the DF program, funding is available for Polkadot-focused organizations that aim to generate profit, as well as for non-profits that have a strategy to secure ongoing financing through Polkadot’s onchain treasury system. An initial $20M plus 5M DOT tokens have been allocated to Decentralized Futures to expand the Polkadot ecosystem.

About PolkaPort East

Based in Hong Kong, PolkaPort East is an organization tasked with spurring adoption of the Polkadot ecosystem in Asia with a focus on Hong Kong and the Greater Bay Area. By working with different entities ranging from developers to investors, PolkaPort East will help to fuel adoption of web3 technology and onboard new users to Polkadot.

Contact

DIrector
Thibault Perréard
Polkaport East
[email protected]

PostAd_coinrule_banner728x90

Comments are closed.

Keiretsu Forum Announces Dr. Martin Gershon as Keynote Speaker for 2024 Investor Capital Expo

2024-10-02T11:08:00Z

PHILADELPHIA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum, the world's largest and most active accredited angel investor network, is proud to announce that Dr. Martin Gershon, a prominent leader in healthcare innovation and venture capital, will deliver the keynote address at the 2024 Investor Capital Expo. This signature event in early-stage investment community will be held on October 31, 2024, at Convene City View in Philadelphia.

Dr. Gershon, Managing Partner and Chief Investment Officer of Endeavor Venture Funds and Endeavor Venture Studio, brings over two decades of experience in life sciences and healthcare startups. His leadership at Endeavor has resulted in over 100 investments and 24 successful exits, solidifying his reputation as a strategic force in healthcare investment. Under his guidance, Endeavor Venture Funds has become synonymous with cutting-edge innovation, most recently, in artificial intelligence (AI)-powered drug discovery.

Recognized as a "Top Voice" in Venture Capital and Entrepreneurship by LinkedIn and named a Top 100 Healthcare Industry Leader by Standard & Poor’s, Dr. Gershon is a sought-after advisor and speaker. His keynote, titled "Pioneering Healthcare Innovation: Investment Strategies in AI Drug Discovery," will delve into the transformative impact of AI on the drug development process. His address will focus on:

  • Investment Opportunities: Exploring high-growth potential in AI-driven drug discovery.
  • Strategic Insights: Understanding how AI is accelerating the development of novel therapeutics.
  • Future Trends: Highlighting upcoming innovations that will shape the life sciences and healthcare sectors.

Keiretsu Forum: A Global Leader in Early-Stage Innovation

Keiretsu Forum continues to be a global leader in early-stage innovation, offering unparalleled access to groundbreaking companies across industries. The Investor Capital Expo serves as the premier gathering for angel investors, venture capitalists, family offices, and entrepreneurs, spotlighting companies that have undergone Keiretsu Forum's rigorous due diligence process. The event provides an invaluable platform for investors to engage with high-potential startups, network with peers, and gain insights from leading industry experts.

Keiretsu Forum has a relationship with Endeavor and Dr Gershon that has at its core aligned vision and lays the solid platform for access to a larger number of remarkable Founder Entrepreneurs and strategic partnerships with the Endeavor investor ecosystem for follow on rounds and sustained growth.

"Dr. Gershon's expertise in healthcare and AI makes him an ideal keynote speaker for this year’s Expo," said Howard Lubert, Regional President of Keiretsu Forum. "His contributions to the commercialization of life-saving technologies and his leadership in AI innovation exemplify the type of visionary thinking that drives the success of early-stage ventures."

Event Details

  • Date: October 31, 2024
  • Time: 8:00 AM – 6:00 PM EDT
  • Location: Convene City View, 30 S 17th St, Philadelphia, PA

Accredited angel investors are encouraged to register for this exclusive event, where they can engage with the next wave of industry disruptors and gain key insights from one of healthcare’s leading innovators.

About Keiretsu Forum :

Keiretsu Forum is the world’s largest private equity angel investment network with 2000+ accredited investors in 35 North American and 23 International chapters, who have invested more than $1B in early-stage companies in the last 23 years.

The Keiretsu Forum portfolio features Entrepreneurs and Companies from Technology-(Internet, Software, Cyber Security, SaaS, Mobile Systems, IoT, etc.), Life Sciences-(Pharma, Medical Devices, Health IT, etc.), FinServ/FinTech, Consumer Products, Clean-Green Energy, Consumer Products, & more!

About Dr. Martin Gershon

Dr. Gershon's career has been marked by his pioneering efforts in healthcare and life sciences innovation. His role at Endeavor Venture Funds connects emerging companies with Fortune 500 partnerships, offering strategic growth solutions and regulatory expertise. Dr. Gershon has advised numerous organizations, including the White House Moonshot CancerX Accelerator, Goldman Sachs, and Bain Capital.

Dr. Gershon’s academic credentials are equally impressive, with advanced training in neuroscience, oncology, and immunology from Harvard, McGill, and Columbia. He has also served as an FDA attorney and has been honored as a Google Scholar in Entrepreneurship.

For media inquiries, please contact:

Cindi Sutera
AMS Communications
[email protected]
610-613-2773


GlobeNewsWire News

Recent Comments